BRT Apartments is an internally managed real estate investment trust that is primarily focused on the ownership, operation and development of multi-family properties. Most of the company's properties are located in the Southeast U.S. and Texas. Generally, the company's multi-family properties are garden apartment, mid-rise or town home style properties that provide residents with amenities, such as a clubhouse, swimming pool, laundry facilities and cable television access. In addition to its multi-family properties, the company owns other real estate assets including undeveloped land, cooperative apartment units and a leasehold position at a commercial property.

Dave & Buster's Entertainment is an owner and operator of entertainment and dining venues (stores) that operate under the name Dave & Buster's. The company's concept is to provide its customers the opportunity to Eat Drink Play and Watch all in one location for adults and families, while serving food and beverages. The company's Eat and Drink is provided through a menu of entrees and appetizers and a selection of non-alcoholic and alcoholic beverages. The company's Play and Watch offerings provide an assortment of entertainment attractions centered around playing games and watching live sports and other televised events.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. The company is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and other hematologic cancers. The company is also developing an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4.

Metropolitan Bank Holding is a bank holding company. Through its wholly owned bank subsidiary, Metropolitan Commercial Bank (the Bank), the company provides a range of business, commercial and retail banking products and services in the New York metropolitan area. The company also provides cash management and retail banking services and serves as an issuing bank for third-party debit card programs nationwide. The Bank accepts deposits from prepaid third-party debit card programs, digital currency customers, its cash management platform provided through various deposit verticals, local businesses, individuals through client referrals and other relationships and through its retail branch network.